Axsome Secures Rights to Novel CNS Drug Candidate
Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced on April 1, 2026, that it has entered into an asset purchase agreement to obtain exclusive global rights to balipodect, a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor from Takeda, according to GlobeNewswire PE. The company plans to develop balipodect for the treatment of schizophrenia and Tourette syndrome, with intentions to begin Phase 3 trial-enabling activities for schizophrenia in 2026. This acquisition expands Axsome’s central nervous system (CNS) portfolio by adding a compound with a new mechanism of action for neuropsychiatric conditions.
Details of the Agreement
Under the terms of the agreement, Axsome obtained worldwide commercial, development, and manufacturing rights to balipodect. Takeda received an upfront payment and is eligible for additional payments tied to development, regulatory, and commercial milestones for the first two indications, as well as royalties on potential global net sales, according to GlobeNewswire PE. Herriot Tabuteau, MD, Chief Executive Officer of Axsome, stated that the addition of balipodect complements the company’s neuroscience pipeline and positions it to advance treatments for conditions like schizophrenia and Tourette syndrome. Balipodect has already completed a 164-patient proof-of-concept Phase 2 trial in schizophrenia and has shown a favorable safety and tolerability profile in clinical studies involving over 360 individuals.
Development and Clinical Background
Axsome intends to focus initially on developing balipodect for schizophrenia, which is characterized by positive symptoms such as hallucinations and delusions, negative symptoms like social withdrawal, and cognitive impairments including memory deficits, as described in the source. The compound’s selective PDE10A inhibition mechanism is potentially first-in-class for these neuropsychiatric conditions. Widely known as a chronic mental health disorder, schizophrenia affects approximately 3.7 million people in the United States and is a leading cause of disability worldwide, though specific treatment advancements remain a focus for biopharmaceutical firms like Axsome. According to GlobeNewswire PE, this move builds on Axsome’s efforts to deliver differentiated options for CNS disorders.
Implications for Neuropsychiatric Treatments
Schizophrenia is associated with impaired daily functioning and reduced life expectancy, impacting a broad spectrum of related psychotic disorders. Axsome’s acquisition of balipodect adds to its portfolio aimed at addressing these challenges, with the drug’s clinical data supporting further development. This strategic step aligns with ongoing industry efforts in CNS therapeutics, as the source highlights the compound’s potential across multiple indications.
